Tuesday, February 24, 2015

Flibanserin: From Antidepressant to maybe Female Viagra ..... Whatever !!!!

Flibanserin is a long-chain arylpiperazine with an interesting story behind it. The molecule is classified as a 5-HT1A agonist and 5-HT2A antagonist, and had initially been developed as an antidepressant. Later it was found that it exerts potential antipsychotic effects. A molecule with multiple indication is good news but "very good news" was still hiding.

All the heavens must have rejoiced when Flibanserin was shortlisted by Boehringer Ingelheim as a drug to boost women sexual desire. Maybe not the Heavens, but surly the CEOs must have. Converting a pill into Bentley via FDA-catalyzed process is all CEOs dream-come-true........

Flibanserin is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). In simple words, the pill will a mood changer for the females, which if you ask any female is not true.

The operating systems (OS) for males and females have very different coding. Males are usually uni-directional beings, as compared to females which are multi-tasking. Male when goes to buy a pair of shoe, he buys a pair of shoe, but a female.... hmmm, we all know the story. So, for such a complex framework, finding any solution is not easy. Maybe the people at FDA thought same, so they gave negative report to Flibanserin, when Boehringer Ingelheim approached them in year 2010.

Heartbroken but able-minded, Boehringer Ingelheim transferred Flibanserin to Sprout Pharmaceuticals which is continuing the drug development process. Now, they have submitted a new report to FDA, with extra information that FDA have asked for.

The entire internet is going GA-GA over this new development, as if we all will get shiny Bentley’s. What we fail to understand is that here is that just few words of respect/love might do the magic for her, what an antidepressant/ antipsychotic/mood-changer hopes to do.  

Sprout Pharmaceuticals achieved approval of the drug by the US FDA in August 2015.